Triglycerides mediate the relationships of per- and poly-fluoroalkyl substance (PFAS) exposure with nonalcoholic fatty liver disease (NAFLD) risk in US participants

Triglycerides mediate the relationships of per- and poly-fluoroalkyl substance (PFAS) exposure with nonalcoholic fatty liver disease (NAFLD) risk in US participants

Nonalcoholic fatty liver disease (NAFLD) is recognized as a significant public health problem worldwide. Several clinical studies have investigated the associations between Per- and poly-fluoroalkyl substances (PFAS) compounds with the risk of NAFLD in general adults, but the mediating effect of tri...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wenying Qiao, Jiashuo Li, Lijia Luo, Wenjuan Peng, Xi Wang, Ronghua Jin, Junnan Li
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Ecotoxicology and Environmental Safety
Subjects:	Per- and poly-fluoroalkyl substances (PFAS) Nonalcoholic fatty liver disease (NAFLD) Triglycerides (TG) Liver function
Online Access:	http://www.sciencedirect.com/science/article/pii/S0147651324015124
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Removal characteristics for nine species of per-and poly-fluoroalkyl substances using different types of anion exchange
by: Heejong Son, et al.
Published: (2024-12-01)

Biomonitoring result of PFAS exposure from Gabreski Air National Firefighting foam among residents in Westhampton, NY
by: Yichun Liu, et al.
Published: (2025-06-01)

Bone cell differentiation and mineralization in wild-type and osteogenesis imperfecta zebrafish are compromised by per- and poly-fluoroalkyl substances (PFAS)
by: Francesca Tonelli, et al.
Published: (2025-01-01)

A review on the recent mechanisms investigation of PFAS electrochemical oxidation degradation: mechanisms, DFT calculation, and pathways
by: Gengyang Li, et al.
Published: (2025-04-01)

The first survey of legacy and emerging per- and polyfluoroalkyl substances (PFAS) in Hulun Lake, China: Occurrence, sources, and environmental impacts
by: Jie Li, et al.
Published: (2025-03-01)

Association between triglyceride-glucose related indices and at-risk NASH in U.S. adults with NAFLD: results from NHANES 2017-2020
by: Hanchen Ma, et al.
Published: (2025-06-01)

Review of roles of RNA-binding proteins on NAFLD and the related pharmaceutical measures
by: Changjin Li, et al.
Published: (2025-05-01)

Association of the p.I148m polymorphism in the <i>PNPLA3</i> gene with the severity of nonalcoholic fatty liver disease in various clinical groups
by: D. V. Sidorenko, et al.
Published: (2024-04-01)

An open-label, controlled trial of the clinical effects of Laennec® in patients with nonalcoholic steatohepatitis or cirrhosis
by: M. Imawari, et al.
Published: (2023-11-01)

Sex differences in ischemic heart disease and evidence gathering related to exposure risk, prevention, and treatment of per- and poly-fluoroalkyl substances
by: Hejun Tian, et al.
Published: (2025-06-01)

Intestinal Microbiota Modulation by Fecal Microbiota Transplantation in Nonalcoholic Fatty Liver Disease
by: Goran Hauser, et al.
Published: (2025-03-01)

Limosilactobacillus mucosae FZJTZ26M3 prevents NAFLD in mice through modulation of lipid metabolism and gut microbiota dysbiosis
by: Danting Dang, et al.
Published: (2024-05-01)

Oxidative stress and inflammation in hemodialysis: a comparison of patients with or without advanced nonalcoholic fatty liver disease (NAFLD)
by: Vanja Kalacun, et al.
Published: (2025-12-01)

The causal impact of body mass index on metabolic biomarkers and nonalcoholic fatty liver disease risk
by: Bo Wang, et al.
Published: (2025-03-01)

Per- and Poly fluoroalkyl Substances Removal using Ion Exchange Resins: A Review
by: Jeongwoo Shin, et al.
Published: (2025-03-01)

Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content
by: Haoxiang Zhu, et al.
Published: (2025-01-01)

Metabolic Syndrome in Adults with Nonalcoholic Fatty Liver Disease
by: Zhahid Hassan, et al.
Published: (2021-09-01)

Advances in per- and polyfluoroalkyl substances (PFAS) detection and removal techniques from drinking water, their limitations, and future outlooks
by: Zahra Zahra, et al.
Published: (2025-03-01)

Effects of laparoscopic sleeve gastrectomy on nonalcoholic fatty liver disease and TGF-β signaling pathway
by: Hideki Kumagai, et al.
Published: (2024-02-01)

Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
by: Apollinariya V. Bogolyubova, et al.
Published: (2017-12-01)

Laparoscopically confirmed endometriosis and the risk of incident NAFLD: a prospective cohort study
by: Hangkai Huang, et al.
Published: (2025-04-01)

Relationship of the Degree of Sarcopenia with the Severity of Nonalcoholic Fatty Liver Disease and Cardiometabolic Risk in Adolescents
by: Yoowon Kwon, et al.
Published: (2024-11-01)

Nonalcoholic fatty liver disease: cause or consequence of insulin resistance?
by: Ekaterina E. Mishina, et al.
Published: (2017-12-01)

Individual and mixtures of PFAS during pregnancy are associated with maternal cardiometabolic outcomes during pregnancy
by: Clark R. Sims, et al.
Published: (2025-04-01)

Value of triglyceride glucose-body mass index in predicting nonalcoholic fatty liver disease in individuals with type 2 diabetes mellitus
by: Xiaoyi Qian, et al.
Published: (2025-01-01)

Features of Glucose Homeostasis and Blood Lipid Spectrum in Patients with Nonalcoholic Fatty Liver Dis ease Depending on the Obesity Degree
by: Korniichuk I., et al.
Published: (2019-04-01)

Noninvasive assessment of nonalcoholic fatty liver disease
by: Gajanan A Rodge, et al.
Published: (2021-01-01)

Associations of perfluoroalkyl substances (PFAS) with terminal ductal lobular unit involution of the normal breast
by: Katherine W. Reeves, et al.
Published: (2025-08-01)

The impact of parity on the risk of nonalcoholic fatty liver disease defined by hepatic steatosis index: A nationwide cohort study
by: So-hyeon Hong, et al.
Published: (2025-07-01)

Mechanistic insights into Y-Box binding protein-1 mediated regulation of lipid metabolism and oxidative stress in NAFLD via INHBE/TNF-β pathway
by: Zhi Ren, et al.
Published: (2024-12-01)

Association between NAFLD and liver fibrosis with nutritional risk index based on the NHANES 2017–2018
by: Jieming Jian, et al.
Published: (2025-01-01)

The prevalence of nonalcoholic fatty liver disease in people living with HIV: a systematic review and meta-analysis
by: Jiaqi Wei, et al.
Published: (2025-02-01)

An insight into the environmental and human health impacts of per- and polyfluoroalkyl substances (PFAS): exploring exposure pathways and their implications
by: Mohammad Hadi Dehghani, et al.
Published: (2025-06-01)

Non-alcoholic fatty liver disease – a rapidly growing indication for liver transplantation in the modern world
by: I. M. Iljinsky, et al.
Published: (2019-10-01)

Evaluating Pediatric NAFLD with Controlled Attenuation Parameter: A Comprehensive Narrative Review
by: Ingrid Arteaga, et al.
Published: (2025-01-01)

Pachymaran alleviates fat accumulation, hepatocyte degeneration, and injury in mice with nonalcoholic fatty liver disease
by: Yu Hong, et al.
Published: (2025-07-01)

Vegetarian diet, food substitution, and nonalcoholic fatty liver
by: Tina H Chiu, et al.
Published: (2018-01-01)

Is nonalcoholic fatty liver disease associated with metabolic syndrome? An experience from a medical college of West Bengal, India
by: Sounak Sinha, et al.
Published: (2025-06-01)

Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease
by: Min Tang, et al.
Published: (2020-01-01)

Non-Invasive Matrices for the Human Biomonitoring of PFAS: An Updated Review of the Scientific Literature
by: Martí Nadal, et al.
Published: (2025-02-01)